{"owner": "ArrayExpress Uploader", "pop_total": 0, "id": 2909, "factors": [{"GSE11959GSM302682": {"compound": "IGF-IR monoclonal antibody - 10H5", "dose": "5"}}, {"GSE11959GSM302682": {"compound": "IGF-IR monoclonal antibody - 10H5", "dose": "5"}}, {"GSE11959GSM302682": {"compound": "IGF-IR monoclonal antibody - 10H5", "dose": "5"}}, {"GSE11959GSM302682": {"compound": "IGF-IR monoclonal antibody - 10H5", "dose": "5"}}, {"GSE11959GSM302678": {"compound": "vehicle control", "dose": "  "}}, {"GSE11959GSM302678": {"compound": "vehicle control", "dose": "  "}}, {"GSE11959GSM302678": {"compound": "vehicle control", "dose": "  "}}, {"GSE11959GSM302678": {"compound": "vehicle control", "dose": "  "}}], "ownerprofile_id": "arrayexpress_sid", "platform": 4, "summary_wrapped": "The insulin-like growth factor (IGF) system consists of two ligands (IGF-I and IGF-II), which both signal through type I IGF receptor...", "pubmed_id": 18790743, "geo_gse_id": "E-GEOD-11959", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 2, "sample_count": 8, "tags": ["breast", "breast cancer", "cancer", "cell", "glucose", "insulin", "neuroblastoma", "surface"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "transcription-profiling-by-array-of-human-sk-n-as", "geo_id_plat": "E-GEOD-11959_A-AFFY-44", "name": "Transcription profiling by array of human SK-N-AS neuroblastoma xenograft tumor treated with anti-human IGF-IR monoclonal antibody (h10H5) to study the anti-tumour function of the antibody", "created": "Sep.03, 2014", "summary": "The insulin-like growth factor (IGF) system consists of two ligands (IGF-I and IGF-II), which both signal through type I IGF receptor (IGF-IR) to stimulate proliferation and inhibit apoptosis, with activity contributing to malignant growth of many types of human cancers. We have developed a humanized, affinity-matured anti-human IGF-IR monoclonal antibody (h10H5), which binds with high affinity and specificity to the extracellular domain. h10H5 inhibits IGF-IR-mediated signaling by blocking IGF-I and IGF-IIbinding and by inducing cell surface receptor down-regulation via internalization and degradation. In vitro, h10H5 exhibits anti-proliferative effects on cancer cell lines. In vivo, h10H5 demonstrates single-agent anti-tumor efficacy in human SK-N-AS neuroblastoma and SW527 breast cancer xenograft models, and even greater efficacy in combination with the chemotherapeutic agent Docetaxel or an anti-VEGF antibody. Anti-tumor activity of h10H5 is associated with decreased AKT activation and glucose uptake, and a 316-gene transcription profile with significant changes involving DNA metabolic and cell cycle machineries. These data support the clinical testing of h10H5 as a biotherapeutic for IGF-IR-dependent human tumors. Experiment Overall Design: Two treatment groups with four tumor samples per group are collected and analyzed,", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-11959", "species": "human", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-11959/samples/"}